Navigation Links
Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Date:5/3/2012

DURHAM, N.C., May 3, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that study results demonstrated that analytical treatment interruption to assess the antiviral activity of Argos's Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004, is an acceptable strategy for at least 16 weeks. Study results were published in the Journal of Medical Virology (84:885–889, 2012).

"Establishing the safety of analytical treatment interruptions of at least 16 weeks is an important step forward in assessing the impact of immunotherapy on viral load control," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "Therapeutic vaccines such as AGS-004 have the potential to decrease long-term antiretroviral therapy which has limitations such as drug toxicity, the risk of developing resistance and others. We look forward to advancing our Phase 2b trial of AGS-004 to further demonstrate its efficacy and safety for the treatment of HIV patients."

The potential risks of short-term interruption of antiretroviral therapy in the AGS-004-001 study were assessed in a retrospective subgroup study analyzing data from patients in the strategies for management of anti-retroviral therapy (SMART) study with matched eligibility criteria. The subgroup analysis included 440 of 2,720 on the drug conservation (DC) arm and 436 of 2,752 on the viral suppression (VS) arm that matched the AGS-004-001 inclusion criteria and were used in the SMART subgroup analysis. In the first 16 weeks following randomization into the SMART study there were no deaths in either subgroup.  There were two AIDS-related events in the DC subgroup and one in the VS subgroup, making the overall risk of AIDS related events two per 100 person years (0.005%) and one per 100 person years (0.002%) in the two subgroups, respectively.  There were
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
... Calif.--(BUSINESS WIRE)--May 31, 2007 - The Waismann,Method ... of Suboxone,users, indicating that 66 percent of ... or Buprenorphine, believe they,cannot stop taking the ... is often prescribed to treat,dependency to opiates ...
Cached Medicine Technology:CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2Waismann Method Survey Reveals Dependency Risk for People Using,Suboxone 2
(Date:1/22/2015)... 22, 2015 Deer Path of Huntley ... Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. on ... Parkway in Huntley, Illinois, serves adults with physical disabilities between the ... include Valentine's Day treats, games and sweetheart-themed karaoke. , For more ...
(Date:1/22/2015)... 22, 2015 Liberty University has received accreditation ... program from the Council for Accreditation of Counseling & ... Liberty’s Center for Counseling & Family Studies , is ... the university’s new School of Behavioral Sciences. Prior to the ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... products. Same flavors. Fewer caloriesFORT WORTH, Texas, ... the Hispanic baking industry by becoming the ... line of 100 Calorie products. Building on ... the 100 Calorie line offers the perfect ...
... new study suggests , , MONDAY, Feb. 16 (HealthDay News) -- ... sleep it off, but they run the risk of developing ... cycle of headaches, a new study shows. , "Going to ... treat their headaches, and they rated it a very effective ...
... LLC, the nation,s leading provider of telemedicine health ... offshore medical service that connects remote workers with ... combines advanced telemedicine technology and medical services to ... Offshore rig and remote workers gain access to ...
... ARLINGTON, Texas, Feb. 16 Across the nation, countless ... executives at one North Texas healthcare company took some ... from being another victim to the economic crisis.2009 looks ... now in its 7th year. One year ago ten ...
... their electroplating, anodizing, and electropolishing plant. , ... Toccoa, ... completion of their new 16, long, 27 station aluminum anodizing line. ... works for some time now and even though the economy is ...
... screening, they say , , MONDAY, Feb. 16 ... screening and diagnostic for breast cancer, not serve as ... guidelines. , The guidelines, published Monday in the ... give needed direction for using breast MRI, a relatively ...
Cached Medicine News:Health News:Marinela USA(R) Launches 100 Calorie Product Line 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 3Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 2Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 3Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 4Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 5Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 6Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 7Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 8Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 9Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 10Health News:Staying Healthy in 2009 2Health News:Experts Release Guidelines on Use of Breast MRI 2
... Ulti-Mist™ HME product line has the right ... to adults and from intubated patients to ... humidification for both anesthesia and critical care ... provide maximum protection for patients and staff ...
... HME product line has the right product ... adults and from intubated patients to patients ... for both anesthesia and critical care applications., ... maximum protection for patients and staff members. ...
... (HCH) capture the patient`s exhaled heat and ... gas. Small and compact, they are specially ... Depending on the tidal volume requirements, select ... ,The adult HCH is ideal for patient ...
... capture the patient`s exhaled heat and moisture ... Small and compact, they are specially treated ... on the tidal volume requirements, select either ... adult HCH is ideal for patient tidal ...
Medicine Products: